The sequencing instrument developer is in the process of scaling and optimizing its silicon chips and plans to offer its platform by the end of next year.
Researchers found that 61 percent of patients they analyzed carried germline pathogenic or likely pathogenic variants in candidate cancer predisposition genes.
HTG terminated a companion diagnostic development deal with Qiagen in the wake of that company's discontinuation of next-generation sequencing instruments.
During a conference call to discuss the firm's second-quarter results, CEO and President Francis deSouza also highlighted potential growth from clinical sequencing.
Practical, technological, and systemic challenges are putting pathologists in tough positions, facing competing demands for molecular analysis of limited biological samples.
Investigators from a variety of clinical sites found that the company's liquid biopsy test was more successful in finding actionable mutations in patients than tumor tissue.
